Togha, M., Karvigh, S. A., Nabavi, M., Moghadam, N. B., Harirchian, M. H., Sahraian, M. A., Enzevaei, A., Nourian, A., Ghanaati, H., Firouznia, K., Jannati, A., & Shekiba, M. (2010). Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.. Multiple Sclerosis (Houndmills, Basingstoke, England), 16(7), 848–854.
Abstract
This study was conducted to evaluate the effect of simvastatin (40 mg/day) as an adjuvant therapy to interferon beta (IFNb 1a, 30 microg once weekly) in relapsing-remitting multiple sclerosis patients, compared with placebo.
Last updated on 02/25/2023